The verdictOn growth, the evidence leans bullish. On cash economics, it leans bearish: Real is still taking share: agents +26%, transactions +27% in a flat market. The loan covenant gives about 30% EBITDA headroom. But Real's last-twelve-month adjusted EBITDA ($77.0M) is almost exactly matched by its stock compensation ($76.4M). RE/MAX's US core keeps shrinking. The new $550M loan costs at least 8.5% just as mortgages hit…
Written by Claude (Anthropic’s AI) from public sources · Willem owns REAX · AI can make mistakes — numbers in brackets point to the sources · Not financial advice
Bull arguments show how well they survive the devil’s advocate (strong / medium / weak); bear arguments show the damage they could do after the counter-argument (high / medium / low).
The point: almost all of Real's adjusted EBITDA is SBC (stock-based compensation) that is added back. Most of it is commission paid to agents in shares. On a cash-to-shareholders basis, Real roughly breaks even.
Evidence:
| Real, last four quarters | Q3'25 | Q4'25 | Q1'26 | Q2'26 | Total |
|---|---|---|---|---|---|
| Adjusted EBITDA | $20.4M | $14.2M | $14.9M | $27.6M | $77.0M |
| SBC | $19.9M | $17.7M | $17.0M | $21.8M | $76.4M |
Why it matters:
🛡️ Counter-argument:
Severity: High. This is the core reason a "6x EBITDA" stock is not obviously cheap.
RE/MAX US agents [14,16,20]:
| Year | US agents |
|---|---|
| 2021 | 61,327 |
| 2022 | 58,719 |
| 2023 | 55,131 |
| 2024 | 51,286 |
| 2025 | 48,165 |
| Jun 2026 | 47,170 |
That is −23% in 4.5 years, and 14 straight quarters of decline [35].
A US company-owned-region agent is worth about $2,565 a year of fees. A global-region agent is worth about $225 [16].
Aspire and Ascend cut fees by up to ~45%. Continuing franchise fees fell 11.4% in Q2'26 [14,16].
Capped agents produced 42% of Q2 sides (+3 pp) [12].
Gross margin by quarter [11,13]:
| Quarter | Gross margin |
|---|---|
| Q2'25 | 8.9% |
| Q3'25 | ~7.9% |
| Q4'25 | 7.7% |
| Q1'26 | 9.05% |
| Q2'26 | 8.3% |
Management guided a year-on-year decline in Q3 gross margin [12].
Revenue share costs 3.2% of revenue [11].
No consensus exists for the combined company (searched StockAnalysis, MarketBeat, Yahoo and Investing.com [44,45]). As the baseline I therefore use management's ~$190M run-rate adjusted EBITDA "floor" for FY2027 [12]. I size impacts in adjusted EBITDA per share (36.56M shares; baseline ≈ $5.20). GAAP EPS is negative and distorted by deal costs, so it is not meaningful. FY2027 revenue reference: about $3.77B, the sum of the two S-4 management plans [9]. This is not consensus.
September fee increases lift Real's margin — 55% chance of showing up as ≥ +$6M a year by FY2027
Revenue synergies from cross-selling into RE/MAX — 20% chance of adding ≥ $15M EBITDA by FY2028
Cost synergies above $30M — 30% chance of a raised target (≥ $40M) by FY2028
Housing volume rebounds beyond forecasts — 15% chance that 2028 US existing-home sales reach ≥ 4.6M
Term-loan repricing — 25% chance by end-2028
Higher-for-longer rates keep 2027 home sales flat — 45% chance in FY2027
RE/MAX US attrition accelerates after close — 30% chance that US agents fall more than 8% year on year in any 2027 quarter
Covenant pressure forces an equity raise — 7% chance within 36 months
Motto wind-down costs more than expected — 50% chance that most remaining offices exit by end-2027
Faster dilution as the share price falls — 40% chance that the share count grows more than 5% a year through FY2027
Liniger block sale — 35% chance of sales above 2M shares within 24 months
Sitzer objectors win Supreme Court review — 3% chance
| # | Factor | Weight | Measured value | Score | Why |
|---|---|---|---|---|---|
| 1 | Liquidity & funding runway | 15% | FCF-positive before SBC (Real H1 operating cash flow ex-escrow ≈ $42M; RE/MAX FY25 adjusted FCF $31.8M); post-close cash ≈ $110–180M (estimate, not reported) + $40M revolver; mandatory debt service ≈ $88M/yr | 48 | Positive cash generation, but debt service takes most of it, and the actual cash balance is unknown until about 2026-11-03. |
| 2 | Leverage | 10% | Net debt ≈ $370–440M (estimate) ÷ $156.6M ≈ 2.4–2.8x; covenant ratio ≈ 3.1x (cash netting capped at $50M); ≈ 5–6x on EBITDA after SBC | 58 | In the 1.5–3x band on adjusted EBITDA, but the SBC add-back makes the economic leverage much higher. |
| 3 | Dilution | 10% | Real issued ~0.74M shares in H1'26 (≈ 2% of the combined 36.56M; ≈ 4% a year); overhang ≈ 2.5M converted RE/MAX RSUs (6.8%) + Real RSUs/options; buyback capped at ~$35M | 55 | The +3–10% band, plus a meaningful overhang. The 14.5M merger shares are deal consideration, not counted as dilution. |
| 4 | Profitability | 10% | Pro forma 2025 adjusted EBITDA $156.6M on ~$2.26B revenue (6.9%); after SBC ≈ $72M (3.2%); Real Q2 GAAP net loss $8.0M | 52 | Around break-even on a cash-to-shareholders basis once SBC and interest are counted. |
| 5 | Revenue quality & concentration | 10% | No customer above 1%; RE/MAX 65.5% recurring but only ~13% of combined revenue; Real >99% transaction commissions | 40 | Diversified across 180k+ agents, but mostly per-transaction revenue. |
| 6 | Execution & track record | 10% | RE/MAX hit its EBITDA guide 4 of 4 times; Real gives no numeric guidance and met its growth claims; synergy timing moved 3 times; Motto U-turn | 48 | A mixed record: clean numeric delivery, but slipping deal promises. |
| 7 | Competitive position & disruption | 10% | Real gaining share (+27% transactions vs a +3.5% market); RE/MAX US agents −23% since 2021; Zillow moving into agent tools and lending | 60 | One engine is winning and the other is losing ground. Contested overall. |
| 8 | Cyclicality & macro sensitivity | 10% | US sales 3.98M; mortgages 7.40%; RE/MAX revenue −7.8%/−5.5%/−5.2% in 2023–25; floating-rate debt | 58 | Volume-linked revenue plus floating-rate debt. Real's share gains cushion it. |
| 9 | Regulatory, legal & geopolitical | 5% | Sitzer affirmed and mandate issued; Batton final approval; Canada Competition Bureau probe; contractor-classification risk; US–Canada tariffs | 35 | Manageable. The big tail risk is resolved. |
| 10 | Valuation & expectations | 10% | EV ≈ $0.94–1.01B ≈ 6.0–6.5x adjusted EBITDA, ~13–14x after SBC; short interest ≈ 3.5%, 1.3–1.9 days to cover; −57% year to date | 35 | Fair. Low expectations and a low short base, but not cheap on cash earnings. |
Overall: weighted average = 0.15×48 + 0.10×58 + 0.10×55 + 0.10×52 + 0.10×40 + 0.10×48 + 0.10×60 + 0.10×58 + 0.05×35 + 0.10×35 = 49.55 → 50.
Change vs last: −13 (63 → 50).
Ranking check: REAX (50) sits clearly below IPX (67), the only other holding scored on this method so far. That is consistent: REAX has revenue, positive pre-SBC cash flow and no customer concentration, while IPX is pre-revenue. Under the old 6-area method REAX (63) sat between APP (47) and DUOT (66).